Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 1Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2Thoracic 1Other solid neoplasm 1Dermatologic 1CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 121Melanoma 111Neoplasms 66Carcinoma, Renal Cell 60Colorectal Neoplasms 43Neoplasm Metastasis 39Squamous Cell Carcinoma of Head and Neck 36Stomach Neoplasms 35Carcinoma, Hepatocellular 33Carcinoma, Transitional Cell 27Lung Neoplasms 23Pancreatic Neoplasms 22Triple Negative Breast Neoplasms 21Ovarian Neoplasms 21Head and Neck Neoplasms 21Advanced Cancer 19Breast Neoplasms 17Urinary Bladder Neoplasms 15Small Cell Lung Carcinoma 14Kidney Neoplasms 13Recurrence 11Hodgkin Disease 11Uterine Cervical Neoplasms 10Skin Neoplasms 10Lymphoma 10Solid Tumor 9Mesothelioma 9Endometrial Neoplasms 9Carcinoma, Merkel Cell 9Carcinoma 9

Interventions

relacorilant 3Nivolumab 2pembrolizumab 1milademetan 1avelumab 1TKM-080301 1N-Ac-CHAVC-NH2 1N-(2,6-bis(1-methylethyl)phenyl)-N'-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride 1IPI-549 1Fentanyl 1E-7386 13-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Adrenocortical Carcinoma × Nivolumab × Clear all
NCT04187404 2026-01-30

Spencer

Enterome

Phase 1/2 Terminated
70 enrolled 20 charts
CNSEndocrine

Paraganglioma, Pheochromocytoma, Adrenocortical Carcinoma

NCT02637531 2022-04-04

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

Infinity Pharmaceuticals, Inc.

Phase 1 Unknown
219 enrolled
BreastDermatologicEndocrineOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Mesothelioma, Adrenocortical Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡